Obesity Hypoventilation Syndrome (Pickwickian Syndrome): Diagnosis, CPAP and Weight Loss

Obesity hypoventilation syndrome (OHS), once called Pickwickian syndrome, is the most severe breathing problem caused by obesity. It is defined by three things together: a BMI of 30 or more, too much carbon dioxide in the blood while awake (an arterial PaCO2 of 45 mm Hg or higher), and disordered breathing during sleep, once other causes of under-breathing have been ruled out ^[1]. About 90% of people with OHS also have obstructive sleep apnea ^[1]. It is linked to heart failure, pulmonary hypertension, hospital admissions and early death ^[1][4]. Nightly positive airway pressure is the first treatment, and sustained weight loss of 25% to 30% is what the American Thoracic Society suggests to make the condition go away ^[1].

The honest summary

• It is defined by a blood test, not a scale. OHS needs obesity plus a high awake carbon dioxide level, after other causes are excluded ^[1].
• It usually travels with sleep apnea. About 90% of people with OHS have obstructive sleep apnea, and nearly 70% have the severe form ^[1].
• It is under-recognized and dangerous. In one hospital study, 31% of severely obese inpatients had unexplained hypoventilation, and 18-month mortality was 23% versus 9% without it ^[4].
• CPAP is the usual first treatment when severe sleep apnea is present. In the Pickwick trial, CPAP and noninvasive ventilation had similar long-term results ^[9].
• Weight loss is the only treatment that can resolve it. The ATS target is a sustained 25% to 30% loss, which bariatric surgery reaches more often than lifestyle programs ^[1][14].
• GLP-1 drugs have not been tested in OHS. The tirzepatide sleep apnea trials excluded people with OHS or daytime hypercapnia ^[17].

What is obesity hypoventilation syndrome?

Hypoventilation means breathing too little to clear carbon dioxide. In OHS, the extra weight on the chest and abdomen, changes in how the brain drives breathing, and repeated breathing problems during sleep combine so that carbon dioxide stays high even during the day ^[2]. The name “Pickwickian syndrome” comes from a 1956 paper that described extreme obesity with alveolar hypoventilation and called it “a Pickwickian syndrome” ^[3], after Joe, the obese, sleepy, snoring “fat boy” with swollen legs in Charles Dickens’s 1836 novel The Pickwick Papers ^[22].

Typical signs listed by the American Thoracic Society include shortness of breath, swelling of the lower legs, getting up at night to urinate, excessive daytime sleepiness, fatigue, loud snoring and witnessed pauses in breathing, along with low oxygen levels, especially during sleep ^[1]. Many of these overlap with ordinary sleep apnea, which is one reason OHS is missed. It is often first diagnosed during an emergency, when a person is admitted with respiratory failure, rather than in a clinic ^[2]. The most common accompanying conditions are heart failure, coronary disease and pulmonary hypertension ^[2].

How OHS is diagnosed

The diagnosis rests on an arterial blood gas showing an awake, resting PaCO2 of at least 45 mm Hg at sea level in someone with a BMI of 30 or more, plus a sleep study to define the breathing pattern at night ^[1]. The sleep study matters because it decides the treatment: about 90% of people with OHS have obstructive sleep apnea, nearly 70% have severe sleep apnea, and the remaining 10% have under-breathing during sleep without obstruction ^[1]. Other causes of high carbon dioxide, such as lung disease, nerve or muscle disease, or chest-wall problems, have to be excluded.

Because arterial blood gases are not routine, guidelines use serum bicarbonate as a screening test. Bicarbonate rises when the body compensates for long-standing high carbon dioxide. In a sleep clinic study, a bicarbonate level of 27 mEq/L or higher caught 92% of people with hypercapnia, while only 3% of people below that level had it ^[6]. The ATS guideline suggests using a bicarbonate below 27 mmol/L to rule out OHS when suspicion is low, and going straight to an arterial blood gas when suspicion is high ^[1]. Bicarbonate is imperfect: it can also be raised by other illnesses and medicines ^[5], and OHS specialists have noted its limits as a screening tool now that GLP-1 drugs and SGLT2 inhibitors are widely prescribed ^[20].

How common is it?

Estimates depend heavily on who is tested. A European respiratory review put the prevalence at roughly 0.4% of adults ^[2]. Among ambulatory adults with obesity screened in French community laboratories, the rate was about 1.1% ^[5]. It is far higher in people already referred for sleep problems: 20% to 30% of patients with obstructive sleep apnea in one U.S. sleep clinic ^[6], and 8% to 20% of obese patients referred to sleep centers across studies ^[1].

Risk climbs with body weight. In 522 people having bariatric surgery in China, 15.1% had OHS, rising from 4.1% at a BMI under 35 to 39.1% at a BMI of 50 or above, and men were affected more often than women (22.8% versus 9.4%) ^[7]. Only 11.4% of those with OHS in that group had no sleep apnea.

Why it matters: outcomes without treatment

The clearest warning comes from a U.S. study of consecutive medical admissions ^[4]. Among 150 hospitalized adults with a BMI of 35 or more, 31% had hypoventilation with no other explanation. They were more likely to need mechanical ventilation and long-term care after discharge, and only 13% were sent home on treatment for it. At 18 months, 23% had died, compared with 9% of similarly obese patients without hypoventilation (hazard ratio 4.0).

Treatment: CPAP or noninvasive ventilation

Positive airway pressure during sleep is the core treatment. A systematic review for the ATS guideline found that treatment was associated with more frequent resolution of OHS and with lower mortality, better gas exchange, less daytime sleepiness, better sleep and quality of life, and fewer emergency visits, though most of the evidence was of low or very low certainty ^[12]. There are two main kinds: CPAP, which holds the airway open with a single steady pressure, and noninvasive ventilation (NIV, often called BiPAP), which also pushes extra air in with each breath.

The Spanish Pickwick program, the largest set of randomized trials in OHS, compared them directly:

• Short term (2 months), OHS with severe sleep apnea. Among 221 randomized patients, both NIV and CPAP improved symptoms and sleep measures more than lifestyle advice alone. NIV gave the largest drop in carbon dioxide, though not significantly more than CPAP, and improved lung function and walking distance more than CPAP did ^[8].
• Long term (median 5.4 years), OHS with severe sleep apnea. Hospital days per patient-year were similar with CPAP (1.63) and NIV (1.44), with no meaningful difference and similar side effects. Because CPAP is simpler and cheaper, the authors suggested it as the preferred first choice ^[9].
• Long term (median 5.0 years), OHS without severe sleep apnea. In 98 patients, NIV did not reduce hospital days compared with lifestyle advice (2.71 versus 2.60 per year), but it did improve carbon dioxide levels, quality of life and sleepiness. People who used NIV consistently did better than those who did not ^[10].

Those trials shaped the ATS guideline, which suggests CPAP rather than NIV as the first treatment for stable outpatients with OHS and severe sleep apnea ^[1]. NIV is preferred for the minority with little or no obstructive apnea, and for people with acute respiratory failure ^[2]. Setting up NIV is also getting simpler: a 2026 randomized trial of 205 patients found that a self-adjusting NIV device lowered carbon dioxide as much as a manually titrated one over 12 months (by about 9 mm Hg in both groups) and cost less ^[11].

For people leaving hospital after an episode of respiratory failure with suspected OHS, the guideline suggests going home on NIV until outpatient testing is done, ideally within two to three months ^[1]. That suggestion rests on an analysis of 1,162 patients from observational studies, in which discharge on positive airway pressure was associated with markedly lower three-month mortality (relative risk 0.12); there were no randomized trials ^[13].

Weight loss: the treatment that can make OHS go away

Breathing machines control OHS; they do not remove the cause. The ATS guideline suggests weight-loss interventions that produce a sustained loss of 25% to 30% of body weight, the amount most likely to resolve the hypoventilation, and notes that this is more likely to be reached with bariatric surgery ^[1].

The evidence behind that target is thin. The systematic review that informed it found only six studies, with 16 to 63 participants each ^[14]. Comprehensive lifestyle programs produced 6% to 7% weight loss and no clinically meaningful benefit over standard care. Bariatric surgery produced 15% to 64.6% weight loss depending on the operation, reduced sleep apnea severity by 18% to 44%, lowered carbon dioxide by 17% to 20%, and led to resolution of OHS; daytime sleepiness and pulmonary artery pressure also improved. About one in five surgical patients had an adverse effect, but serious complications were very rare. Certainty was very low for most outcomes.

Positive airway pressure itself does not explain weight change. An analysis of three randomized trials with 342 people with OHS found a small, similar drop in BMI (about 0.5) whether or not they received positive airway pressure, with no link to how much they used it ^[15]. For a side-by-side look at surgery and medicines, see bariatric surgery versus GLP-1 drugs, and for how the operations compare on safety, the safest form of weight-loss surgery.

What about GLP-1 drugs like tirzepatide?

This is where precision matters. Tirzepatide (Zepbound) has strong randomized evidence in obstructive sleep apnea, not in OHS. In the two SURMOUNT-OSA trials, adults with obesity and moderate-to-severe sleep apnea who took tirzepatide for 52 weeks had about 20 to 24 fewer breathing events per hour than those on placebo, along with lower body weight, blood pressure and inflammation ^[16]. The details are covered in SURMOUNT-OSA: tirzepatide for sleep apnea.

But the trial registry lists “Diagnosis of Obesity Hypoventilation Syndrome or daytime hypercapnia” among its exclusion criteria ^[17]. People with OHS were deliberately kept out. Zepbound’s approved use reflects that trial population:

“to treat moderate to severe obstructive sleep apnea (OSA) in adults with obesity.” ^[18]

— ZEPBOUND prescribing information, Indications and Usage (DailyMed)

A 2025 review of OHS care described GLP-1 receptor agonists as promising but noted that they have not yet been specifically studied in OHS populations ^[19]. Because nearly all people with OHS have obstructive sleep apnea and weight loss is the one treatment that can reverse it, the drugs are a logical candidate, and many people with OHS will qualify for them through their obesity or their sleep apnea. Whether a GLP-1 drug can produce the 25% to 30% sustained loss the guideline targets, and whether that resolves the hypoventilation, has not been tested.

One caution is worth knowing. A 2026 case report described a 40-year-old with obesity who developed daytime sleepiness, morning headaches and high carbon dioxide without sleep apnea four weeks after semaglutide was increased to 1 mg; the problem resolved after the drug was stopped and temporary NIV was used ^[21]. A single case cannot show cause and effect, but it is a reason to report new sleepiness or morning headaches to your clinician. Our GLP-1 and sleep apnea patient guide explains why CPAP should not be stopped on the strength of weight loss alone without a repeat sleep study.

OHS, sleep apnea and snoring: how they relate

Snoring, obstructive sleep apnea and OHS sit on a spectrum of obesity-related breathing problems. Snoring alone is common and often harmless; sleep apnea adds repeated airway collapse during sleep; OHS adds a carbon dioxide level that stays high even when awake, and almost everyone with OHS also has sleep apnea ^[1]. Weight loss helps at every step, as covered in does losing weight stop snoring. The heart strain that OHS can cause also overlaps with obesity-related heart failure, discussed in GLP-1 drugs and heart failure with preserved ejection fraction, and other obesity-related lung conditions are reviewed in GLP-1 drugs, asthma and COPD.

Practical guidance

• Know the warning signs. Breathlessness, leg swelling and persistent sleepiness in someone with obesity and sleep apnea deserve a bicarbonate or blood gas check ^[1].
• Use the machine. Consistent use of positive airway pressure is linked to better outcomes ^[10][12].
• After a hospital stay for breathing failure, do not go home without a plan. Discharge on NIV was associated with much lower short-term mortality ^[13].
• Treat weight loss as the long-term goal. The guideline target is a sustained 25% to 30% loss; ask whether bariatric surgery is an option ^[1].
• If you start a GLP-1 drug, keep your breathing treatment until a specialist re-tests you; the drugs have not been studied in OHS ^[17][19].